Health Catalyst names Ben Albert as president and COO

SALT LAKE CITY - Health Catalyst, Inc. (NASDAQ:HCAT), a healthcare data and analytics company with annual revenue of $316 million and an overall "GOOD" financial health rating according to InvestingPro, appointed Ben Albert as President and Chief Operating Officer, the company announced Wednesday.

Albert previously served as CEO and Co-Founder of Upfront Healthcare Services until its acquisition by Health Catalyst in January. He brings over 25 years of experience building healthcare organizations focused on patient activation and improving clinical, financial, and operational outcomes. The appointment comes at a crucial time for Health Catalyst, which InvestingPro analysis suggests is currently undervalued, with analysts projecting profitability this year despite recent challenges.

In his new role, Albert will oversee day-to-day operations with senior leaders in Product Engineering, Technology Delivery and Support, Growth, Operations, Finance, and Corporate Strategy reporting to him.

The appointment comes as current CEO Dan Burton prepares for his previously announced retirement in June 2026. Burton will remain focused on investor relationships and customer growth until his departure. The board continues its search for the next CEO.

As Albert transitions into his new position, Dan LeSueur will end his full-time service with Health Catalyst and is expected to move into a part-time advisory role.

"I’m honored to lead our talented team through this important chapter," Albert said. "Health Catalyst delivers measurable improvement in healthcare better than anyone, and we will continue to build on that strength."

Jack Kane, Chair of the Health Catalyst Board, expressed confidence that Albert’s leadership would help the company "accelerate and amplify its progress and evolution, and drive shareholder value."

Health Catalyst provides data and analytics technology to more than 1,000 healthcare organizations worldwide, according to the company’s press release statement. The company maintains a solid current ratio of 1.83 and has shown revenue growth of 5.55% over the last twelve months. For deeper insights into Health Catalyst’s performance and outlook, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s financial health and growth prospects.

In other recent news, Health Catalyst has been the focus of various analyst updates and strategic partnerships. Canaccord Genuity lowered its price target for Health Catalyst to $5.00 from $9.00, citing growth concerns but maintaining a Buy rating. Meanwhile, Piper Sandler downgraded the company from Overweight to Neutral, reducing the price target to $4.00 from $8.00 due to disappointing first-half 2025 bookings and revised revenue guidance for the year. Evercore ISI, however, raised its price target to $4.00 from $3.00, following discussions with Health Catalyst management about ongoing developments and the rollout of the Ignite platform.

Additionally, Health Catalyst has formed a new partnership with CyncHealth Nebraska to enhance the exchange of patient data among healthcare providers. This collaboration aims to improve the accuracy, timeliness, and security of Continuity of Care Documents, which are crucial for clinical decision-making. Cantor Fitzgerald maintained a Neutral rating with a $4.00 price target, noting a more optimistic political environment assessment by Health Catalyst. The company’s management believes its client base is adjusting its budgeting approach in light of Medicaid cuts. These developments reflect a dynamic period for Health Catalyst as it navigates growth challenges and strategic opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.